Previous pre-clinical studies have redirected CAR-modified primary human NK cells against CD19 [26, 27], CD20 [28], CD244 [29], and HER2 [30], and anti-CD19 CAR-modified donor-derived and haploidentical NK cells have successfully entered clinical trials for B-cell acute lymphoblastic leukemia (NCT00995137 and NCT01974479). The gene discussed is CD19; the disease is B-cell acute lymphoblastic leukemia.